Promoter holding
64.27%
PL
Premas Life Sciences Private Limited - Due diligence report
A 360° intelligence report on Premas Life Sciences: trust score, financial health, credit view, compliance, directors, growth and distress s…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹349
50% off
New user
Or enjoy up to 50% off with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Premas Life Sciences — 360° Intelligence Report
Generated from MCA filings & public records80/100
Trust Score
Low Risk
Premas Life Sciences is assessed as Low Risk with a Trust Score of 80/100. Premas Life Sciences is an active private limited indian non-government company incorporated in 2011, operating in the Healthcare sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.
Report generated on 05 Jul 2026 from the latest processed filings. Premas Life Sciences Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
80/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
64/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
80/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
95/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
75/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 95/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- Moderate gearing (D/E 1.42).
- Working-capital cover adequate.
- Profitable - internal accruals available.
Charges position: 3 open (132.00 cr) · 0 satisfied (-).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Hdfc Bank Limited | 1 | 48.0 cr |
| Others | 1 | 48.0 cr |
| Citi Bank N.A. | 1 | 48.0 cr |
Compliance Score: 64/100 Moderate
- Company status is Active as per MCA.
- Balance sheet slightly behind (Mar 2024).
- Litigation present in 2 court forum(s).
- 1 auditor resignation(s) filed - latest: Agarwal N & Co. on 2016-07-10.
- 1 active GST registration(s).
Legal cases on record (2)
05
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| RITIKA . MUNDRA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ASHOK JAIN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| DEBJIT PATRA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| PRAVEEN KUMAR GUPTA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ASHOK JAIN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| AVIJIT DAS | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 6 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
5 allotment(s) · 3 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
Key managerial personnel: ASHOK JAIN (CFO) · PRAVEEN KUMAR GUPTA (Managing Director) · ASHOK JAIN (CFO)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 75 · Distress 75
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
EPFO headcount growing - hiring signal.
Operating for 15+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
3 open charge(s) registered - assets are encumbered.
1 auditor resignation(s) on record - review the stated reasons.
2 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence72/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment83/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 3 open charge(s) of 132.00 cr already registered.
- Compliance gaps should be priced into terms.
Investor view78/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 2 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events28 Aug 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
16 Feb 2023
Director appointed
RITIKA . MUNDRA (Company Secretary)
09 Sep 2022
Director appointed
ASHOK JAIN (CFO)
22 Dec 2021
Charge created
Others - 27.00 cr
29 Nov 2021
Charge created
Hdfc Bank Limited - 80.00 cr
21 Apr 2021
Securities allotted
89973 Equity Shares - 17.99 Lakh raised
31 Mar 2020
Share transfer (FY 2020)
125.00000000 shares to ASHOK JAIN
31 Mar 2019
Share transfer (FY 2019)
240.00000000 shares to Ashok Jain
14 Mar 2019
Charge created
Citi Bank N.A. - 25.00 cr
17 Jul 2018
Director ceased
PRAVEEN KUMAR GUPTA
20 Jan 2018
Securities allotted
15000 Equity Shares - 1.50 Lakh raised
13 Mar 2017
Securities allotted
55818 Equity Shares - 5.58 Lakh raised
07 Feb 2017
Securities allotted
58651 Equity Shares - 5.87 Lakh raised
24 Sep 2016
Director ceased
DEBJIT PATRA
10
Key Observations
Auto-generated from the data aboveRevenue grew 24% over the last 4 financial year(s).
Net profit margin moved from 0.86 to 61%.
Debt-to-equity stands at 38% - manageable leverage.
Net worth is positive.
6 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 5 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Motus Merchandise Private Limited | U51909GJ2019PTC105864 | Surat, Gujarat, India |
| Nakoda Dairy Private Limited | U01520KA2005PTC036883 | Bengaluru, Karnataka, India |
| Magpie Global | U51900MH2006PLC158816 | Mumbai, Maharashtra, India |
| Morvinandan Proteins Limited | U15139MP2013PLC030524 | Neemuch, Madhya Pradesh, India |
| Shribalaji Over Seas | U51496DL2016PTC298462 | New Delhi, Delhi, India |
| R.A.Motors Private Limited | U50101UP2004PTC031382 | Etah, Uttar Pradesh, India |
| Maruti Bitumen Private Limited | U23200GJ2009PTC058458 | Ahmedabad, Gujarat, India |
| Paviter Metals Private Limited | U27100PB2004PTC026967 | Punjab, Punjab, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Premas Life Sciences before audits and certifications: compliance score 64/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Premas Life Sciences: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 95/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 75/100, margin trends, ownership structure and peer set for Premas Life Sciences - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 80/100, distress signals and MSME payment-delay disclosures - know whether Premas Life Sciences pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Premas Life Sciences - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Premas Life Sciences an active company?
Premas Life Sciences has MCA status “Active” with a compliance score of 64/100 (Moderate).
Is Premas Life Sciences financially healthy?
Premas Life Sciences has a Financial Health Score of 80/100 (Low Risk) based on its filed financial statements.
Should I do business with Premas Life Sciences?
Its overall Trust Score is 80/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Premas Life Sciences?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 6 active director(s) are on record.
Does Premas Life Sciences have loans or charges against its assets?
3 open charge(s) are registered against its assets.
Is Premas Life Sciences up to date with its ROC filings?
Balance sheet slightly behind (Mar 2024). Overall compliance score: 64/100 (Moderate).
Is it risky to lend to Premas Life Sciences?
Its Credit Risk Score is 95/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
